


September 20, 2018



Parker Releases New Indego Therapy Exoskeleton

Device offers clinicians the ability to provide custom-tailored gait therapy programs to patients with spinal cord injury and stroke

CLEVELAND, Sept. 20, 2018 (GLOBE NEWSWIRE) -- Parker Hannifin Corporation (NYSE:PH), the global leader in motion and control technologies, today announced the release of its next generation Indego Therapy device for use in rehabilitation centers. The new Indego Therapy is rapidly adjustable and can be custom-sized and perfectly fitted to patients.



“With the new Indego Therapy offering, we have a much more compelling value proposition to clinics and rehabilitation centers both large and small,” said Achilleas Dorotheou, head of the human motion and control business unit for Parker. “It also includes our powerful Therapy+ software suite, which received FDA clearance in February 2018 and provides individualized therapy sessions to stroke and spinal cord injury patients, all at a significantly lower price point.”

The Therapy+ software suite, included with each Indego Therapy device, incorporates control algorithms based on proven motor learning principles and allows for an

individualized, patient-centric training approach where the device responds to a patient's active contribution and assists in gait only when necessary. Additionally, therapists have a range of customizable settings within the Therapy+ software suite which allow them to further tailor the behavior of the system to specific impairment and gait needs.

Clare Hartigan, a physical therapist at the Shepherd Center, was one of numerous therapists who provided feedback to Parker engineers. "One of the best new features of using Indego Therapy is the ability to rapidly adjust all components while the patient is in the device, and at any time while sitting or standing. Therapy+ software allows for setting changes during swing and stance phase for each leg. Whether the goal for the session is gait retraining, neuromuscular re-ed, strengthening, endurance or mobility with high dose steps, I can customize settings for exactly what the patient needs."

The new Indego Therapy device replaces the existing three device Indego Therapy Kit offered to hospitals and rehabilitation centers since 2016, and is now commercially available for customers in the United States and Europe.

To learn more about Indego Therapy visit www.indego.com/therapy

About Indego

With dedicated therapy and personal use exoskeletons, Indego provides solutions that address the complete continuum of care – from acute rehabilitation to home and community ambulation.

Indego Therapy is cleared by the FDA for use with spinal cord injury patients with injury levels C7 to L5, and for individuals with hemiplegia (with motor function of 4/5 in at least one upper extremity) due to cerebrovascular accident (CVA) to perform ambulatory functions in rehabilitation institutions. Indego Personal is cleared by the FDA to enable individuals with spinal cord injury at levels T3 to L5 to perform ambulatory functions in their home and community. Indego Therapy and Indego Personal are also commercially available in Europe, having received the CE Mark in November 2015.

To learn more about Indego Therapy or Indego Personal, visit www.indego.com

About Parker Hannifin

Parker Hannifin is a Fortune 250 global leader in motion and control technologies. For more than 100 years the company has engineered the success of its customers in a wide range of diversified industrial and aerospace markets. Learn more at www.parker.com or @parkerhannifin.

Attachment

- [Parker Releases New Indego Therapy Exoskeleton](#)

Aidan Gormley, Director, Global Communications and Branding
216/896-3258
aidan.gormley@parker.com



Source: Parker-Hannifin Corporation